Rare Disease Expertise On FDA Advisory Committees Gains Capitol Hill Attention
Executive Summary
With Congress watching whether enough experts are on advisory committees for orphan drugs, the US FDA may be pressured into changes.
You may also be interested in...
US FDA Looks To Assure Advisory Committees' Subject Expertise With More Temporary Members
Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.
Expect More Temporary Members Voting In US FDA Advisory Committees
Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.
India Exempts Rare Disease Drugs, Keytruda From Customs Duty - Is It Enough?
India has exempted imports of top-selling oncology drug Merck’s Keytruda from customs duty as also rare disease drugs listed in the National Policy For Rare Diseases. However, patient advocacy groups feel more fiscal measures and manufacturing incentives are needed to improve access